Post mortem validation and mechanistic study of UCB‐J in progressive supranuclear palsy patients’ brains

by Clinical Neuropsychologist | Friday, December 13, 2024 | Dementia

Abstract INTRODUCTION Progressive supranuclear palsy (PSP) is a devastating 4R tauopathy affecting motor functions and is often misdiagnosed/underdiagnosed due to a lack of specific biomarkers. Synaptic loss is an eminent feature of tauopathies including PSP. Novel...

Neuropathology of trisomy 21 mosaicism in a case with early‐onset dementia

by Clinical Neuropsychologist | Tuesday, December 10, 2024 | Dementia

Abstract INTRODUCTION This study investigated the impact of trisomy 21 mosaicism (mT21) on Alzheimer’s disease (AD) neuropathology in a well-characterized clinical case described by Ringman et al. METHODS We describe AD neuropathology in mT21 including amyloid...

Advance care planning in adults ages 80 years and older with impaired cognition: Using actual conversations to examine best practices

by Clinical Neuropsychologist | Tuesday, December 10, 2024 | Dementia

Abstract INTRODUCTION Recommendations for advance care planning (ACP) in persons with cognitive impairment are based on expert input without insight from actual ACP conversations. METHODS We used thematic analysis to analyze transcripts of ACP conversations for 88...

Transethnic analysis identifies SORL1 variants and haplotypes protective against Alzheimer’s disease

by Clinical Neuropsychologist | Tuesday, December 10, 2024 | Dementia

Abstract INTRODUCTION The SORL1 locus exhibits protective effects against Alzheimer’s disease (AD) across ancestries, yet systematic studies in diverse populations are sparse. METHODS Logistic regression identified AD-associated SORL1 haplotypes in East Asian...

Developing and applying potentially scalable recruitment strategies to accelerate ADRD research participation of Black adults

by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia

Abstract More than 2 million older Americans from underrepresented racial and ethnic minority groups (URGs) have early-stage Alzheimer’s disease and related dementias (ADRD). There are very few scalable recruitment strategies, particularly for Black older...

Influence of medical conditions on the diagnostic accuracy of plasma p‐tau217 and p‐tau217/Aβ42

by Clinical Neuropsychologist | Friday, December 6, 2024 | Dementia

Abstract INTRODUCTION Blood-based biomarkers (BBMs) can enable early detection of brain amyloid beta (Aβ) pathology in cognitively unimpaired individuals. However, the extent to which common medical conditions affect biomarker performance remains unclear. METHODS...